The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

DLA Piper LLP (US)

1251 AVENUE OF THE AMERICAS, NEW YORK, NY 10020-1104, USA
Tel:
Work +1 212 335 4500
Fax:
Fax +1 212 335 4501
Web:
www.dlapiper.com

Tom Califano

Tel:
Work +1 212 335 4990
Email:
Web:
www.dlapiper.com/en/us/people/c/califano-thomas-r/
DLA Piper LLP (US)

Work Department

Mergers and Acquisitions; Private Equity; Real Estate; Projects, Energy and Infrastructure; Healthcare; Restructuring; Corporate; Energy and Natural Resources

Position

Partner and US Co-Chair of DLA Piper's Restructuring Practice Group

Career

Tom Califano has a broad-ranging practice in all aspects of insolvency matters, including out-of-court workouts and chapter 11 reorganizations and liquidations.

Tom represents distressed private and public companies, funds, purchasers of distressed debt and parties in interest, including board of directors of distressed companies. His particular emphasis is on company and buyer side representation, and he has extensive experience in healthcare industry restructurings.

Member

American Bankruptcy Institute; Turnaround Management Association; American Health Lawyers Association

Education

J.D. and B.A., St. John's University


United States: Finance

Restructuring (including bankruptcy): corporate

Within: Restructuring (including bankruptcy): corporate

The ‘effective and practical’ DLA Piper LLP (US) provides ‘solution-driven, consensus building and concise advice’, particularly in the healthcare, retail and manufacturing sectors. Chicago-based Richard Chesley jointly leads the practice alongside Tom Califano in New York, and they are supported by the ‘experienced, talented, attentive and creative’ John Lyons, who is ‘able to find imaginative solutions to complicated problems’. The team represented Appvion in its sale to the stalking horse bidder, led by Franklin Advisers, for $365m, in relation to the company’s Chapter 11 filings in the US Bankruptcy Court for the District of Delaware. The team is also representing 4 West Holdings, Orianna Investment and 133 affiliates, collectively, as joint owners of a healthcare business that owns and operates skilled nursing homes across seven states in Chapter 11 proceedings in the US Bankruptcy Court for the Northern District of Texas; the matter included a prepack followed by litigation. Other clients include Gordon Brothers Group, Black Diamond and CenterPoint Properties.

[back to top]

United States: Industry focus

Healthcare: service providers

Within: Healthcare: service providers

The healthcare team at DLA Piper LLP (US) is 'strong in regulatory compliance and all kinds of transactional work', while also offering dispute resolution and data privacy advice. Miami-based practice lead Joshua Kaye, who delivers 'exceptional service, quality of work and attention to detail', assisted Somos Innovation on the establishment of a Medicaid-focused, value-based care system in New York together with Evolent, while well-regarded Philadelphia litigator Brian Benjet advised BioMatrix Specialty Pharmacy and its affiliates on a fraud claim from Highmark under the Racketeer Influenced and Corrupt Organizations Act. Austin partner Karen Nelson - who has 'deep experience and a practical approach' - successfully represented a hospital and health system in its attempt to prove non-compliance of external auditors with the procedural requirements during the client's audit investigation. Tom Califano, who is based in New York, specialises in representing healthcare companies in Chapter 11 proceedings.

[back to top]


Back to index

Legal Developments by:
DLA Piper LLP (US)

  • Sentencing guidelines for corporate manslaughter

    In February 2010 the Sentencing Guidelines Council (the SGC) issued definitive guidelines to courts on imposing appropriate sentences for corporate manslaughter and health and safety offences causing death. The SGC states that fines imposed on companies found guilty of corporate manslaughter should not fall below £500,000, while fines in respect of health and safety offences that are a significant cause of death should be at least £100,000. Crucially, the SGC declined to provide for a fixed link between the imposed fine and the turnover or profitability of the offending company.

    - DLA Piper UK LLP

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to